Adlai Nortye Ltd. American Depositary Shares (ANL) is a publicly traded Healthcare sector company. As of May 21, 2026, ANL trades at $11.36 with a market cap of $747.66M and a P/E ratio of 0.00. ANL moved +7.57% today. Year to date, ANL is +711.43%; over the trailing twelve months it is +514.05%. Its 52-week range spans $0.88 to $17.25. Analyst consensus is strong buy with an average price target of $21.67. Rallies surfaces ANL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Adlai Nortye Doses First U.S. Patient in Phase 1 Pan-RAS Inhibitor Trial: Adlai Nortye dosed the first U.S. patient in its global Phase 1 study of AN9025, an oral pan-RAS(ON) inhibitor targeting advanced solid tumors with RAS mutations. The multicenter trial, conducted in collaboration with ASK Pharm under a regional license agreement, will assess safety, pharmacokinetics and anti-tumor activity.
| Metric | Value |
|---|---|
| Price | $11.36 |
| Market Cap | $747.66M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.25% |
| 52-Week High | $17.25 |
| 52-Week Low | $0.88 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover ANL: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.67.